Ingrid Kromann

3.0k citations

23 papers · 1.4k indexed · h-index 15

Co-authors: Peter Andersen Peter Fibiger Bang Tom H. M. Ottenhoff Jaap T. van Dissel Birgit Thierry-Carstensen Søren T. Hoff Corine Prins Lars Vibe Andreasen
Topics: Tuberculosis Research and Epidemiology (12 papers)vaccines and immunoinformatics approaches (10 papers)Immunodeficiency and Autoimmune Disorders (7 papers)
Cited by: Infectious Diseases Immunology Microbiology
Journals: The Journal of Immunology PLoS ONE American Journal of Respiratory and Critical Care Medicine
Partner nations: Denmark Netherlands United States

In The Last Decade

Ingrid Kromann

23 papers receiving 1.3k citations

Peers

Countries citing papers authored by Ingrid Kromann

Since Specialization

Citations

This map shows the geographic impact of Ingrid Kromann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ingrid Kromann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ingrid Kromann more than expected).

Fields of papers citing papers by Ingrid Kromann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ingrid Kromann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ingrid Kromann. The network helps show where Ingrid Kromann may publish in the future.

Co-authorship network of co-authors of Ingrid Kromann

This figure shows the co-authorship network connecting the top 25 collaborators of Ingrid Kromann. A scholar is included among the top collaborators of Ingrid Kromann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ingrid Kromann. Ingrid Kromann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Strategic Guide to Improve and De-Risk Vaccine Development: CEPI’s CMC Framework 2024 ·PDA Journal of Pharmaceutical Science and Technology ·(unknown),(unknown),Diletta Magini,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Ingrid Kromann	2
2	Safety and Immunogenicity of the H56:IC31 Tuberculosis Vaccine Candidate in Adults Successfully Treated for Drug-Susceptible Pulmonary Tuberculosis: A Phase 1 Randomized Trial 2024 ·The Journal of Infectious Diseases ·Dereck Tait,Andreas H. Diacon,Álvaro H. Borges,Elana van Brakel,David A. Hokey,Kathryn Rutkowski,(unknown),(unknown),Peter Andersen,Ingrid Kromann,Morten Rühwald,Gavin Churchyard,Rodney Dawson	6
3	Availability and use of Standards in vaccine development 2023 ·npj Vaccines ·Michael S. Avumegah,Giada Mattiuzzo,(unknown),Mark Page,Karen W. Makar,(unknown),June Myung Kim,Solomon Abebe Yimer,(unknown),Ivana Knežević,Valentina Bernasconi,Paul A. Kristiansen,Ingrid Kromann	6
4	Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial 2019 ·The Lancet Infectious Diseases ·Sonya Abraham,Helene Bæk Juel,Peter Fibiger Bang,Hannah M. Cheeseman,(unknown),Tom Cole,Max P Kristiansen,Karen Smith Korsholm,David Lewis,Anja Weinreich Olsen,Leon R. McFarlane,Suzanne Day,(unknown),(unknown),Morten Rühwald,Ingrid Kromann,Peter Andersen,Robin J. Shattock,Frank Follmann	135
5	Dose Optimization of H56:IC31 Vaccine for Tuberculosis-Endemic Populations. A Double-Blind, Placebo-controlled, Dose-Selection Trial 2018 ·American Journal of Respiratory and Critical Care Medicine ·Sara Suliman,Angelique Kany Kany Luabeya,Hennie Geldenhuys,Michèle Tameris,Søren T. Hoff,Zhongkai Shi,Dereck Tait,Ingrid Kromann,Morten Rühwald,Kathryn Rutkowski,Barbara Shepherd,David A. Hokey,Ann M. Ginsberg,Willem A. Hanekom,Peter Andersen,Thomas J. Scriba,Mark Hatherill	76
6	A phase I, open-label trial on the safety and immunogenicity of the adjuvanted tuberculosis subunit vaccine H1/IC31® in people living in a TB-endemic area 2018 ·Trials ·Jemal Hussein,Martha Zewdie,Lawrence Yamuah,Ahmed Bedru,Markos Abebe,Alemnew F. Dagnew,(unknown),(unknown),(unknown),Howard Engers,T. Mark Doherty,Peter Fibiger Bang,Ingrid Kromann,Søren T. Hoff,Abraham Aseffa	21
7	Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trials 2017 ·Vaccine ·(unknown),Timo Vesikari,(unknown),Markus Maeurer,Raija Ahmed,(unknown),Sean Bennett,J. Bruce McClain,Barbara Shepherd,Daner Li,David A. Hokey,Ingrid Kromann,Søren T. Hoff,Peter Andersen,Adriëtte W. de Visser,Simone A. Joosten,Tom H. M. Ottenhoff,Jan Andersson,Susanna Brighenti	41
8	Immunogenicity and safety of three aluminium hydroxide adjuvanted vaccines with reduced doses of inactivated polio vaccine (IPV-Al) compared with standard IPV in young infants in the Dominican Republic: a phase 2, non-inferiority, observer-blinded, randomised, and controlled dose investigation trial 2017 ·The Lancet Infectious Diseases ·Luis Rivera,Rasmus S. Pedersen,(unknown),(unknown),Lars Vibe Andreasen,Ingrid Kromann,(unknown),(unknown),Jes Dietrich,Ananda S Bandyopadhyay,Birgit Thierry-Carstensen	9
9	First-in-human safety and immunogenicity investigations of three adjuvanted reduced dose inactivated poliovirus vaccines (IPV-Al SSI) compared to full dose IPV Vaccine SSI when given as a booster vaccination to adolescents with a history of IPV vaccination at 3, 5, 12 months and 5 years of age 2016 ·Vaccine ·(unknown),Pernille N. Tingskov,(unknown),Bettina S. Nedergaard,(unknown),Lars Vibe Andreasen,Ingrid Kromann,(unknown),Jes Dietrich,Birgit Thierry-Carstensen	5
10	Antiviral Innate Immune Activation in HIV-Infected Adults Negatively Affects H1/IC31-Induced Vaccine-Specific Memory CD4⁺T Cells 2015 ·Clinical and Vaccine Immunology ·Nicole Lenz,Tobias Schindler,Benjamin M. Kagina,Jitao David Zhang,(unknown),Maxmillian Mpina,Peter Fibiger Bang,Ingrid Kromann,Søren T. Hoff,Peter Andersen,Klaus Reither,Gavin Churchyard,Ulrich Certa,Claudia Daubenberger	7
11	The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trial 2015 ·Vaccine ·Hennie Geldenhuys,Helen Mearns,David J. C. Miles,Michèle Tameris,David A. Hokey,Zhongkai Shi,Sean Bennett,Peter Andersen,Ingrid Kromann,Søren T. Hoff,Willem A. Hanekom,Hassan Mahomed,Mark Hatherill,Thomas J. Scriba,Michele van Rooyen,J. Bruce McClain,Robert Ryall,Guy de Bruyn	56
12	A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human 2014 ·Vaccine ·Jaap T. van Dissel,Simone A. Joosten,Søren T. Hoff,Darius Soonawala,Corine Prins,David A. Hokey,Dawn M. O’Dee,Andrew J. Graves,Birgit Thierry-Carstensen,Lars Vibe Andreasen,Morten Rühwald,Adriëtte W. de Visser,Else Marie Agger,Tom H. M. Ottenhoff,Ingrid Kromann,Peter Andersen	190
13	Safety and Immunogenicity of H1/IC31®, an Adjuvanted TB Subunit Vaccine, in HIV-Infected Adults with CD4+ Lymphocyte Counts Greater than 350 cells/mm3: A Phase II, Multi-Centre, Double-Blind, Randomized, Placebo-Controlled Trial 2014 ·PLoS ONE ·Klaus Reither,(unknown),(unknown),(unknown),Nicole Lenz,Khadija Said,Elirehema Mfinanga,(unknown),Katherine Fielding,(unknown),Benjamin M. Kagina,E. Jane Hughes,Thomas J. Scriba,Willem A. Hanekom,Søren T. Hoff,Peter Fibiger Bang,Ingrid Kromann,Claudia Daubenberger,Peter Andersen,Gavin Churchyard	49
14	Therapeutic Vaccination Using Cationic Liposome-Adjuvanted HIV Type 1 Peptides Representing HLA-Supertype-Restricted Subdominant T Cell Epitopes: Safety, Immunogenicity, and Feasibility in Guinea-Bissau 2013 ·AIDS Research and Human Retroviruses ·Raúl Gómez Román,Kristoffer Jarlov Jensen,Sanne Jensen,(unknown),Sanne Jespersen,David Te,(unknown),Christoph M. Janitzek,Lasse Vinner,Terese L. Katzenstein,Peter Andersen,Ingrid Kromann,Lars Vibe Andreasen,Ingrid Karlsson,Anders Fomsgaard	46
15	Adjuvanted HLA-supertype restricted subdominant peptides induce new T-cell immunity during untreated HIV-1-infection 2012 ·Clinical Immunology ·Ingrid Karlsson,Lea Brandt,Lasse Vinner,Ingrid Kromann,Lars Vibe Andreasen,Peter Andersen,Jan Gerstoft,Gitte Kronborg,Anders Fomsgaard	36
16	Ag85B–ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection 2011 ·Vaccine ·Jaap T. van Dissel,Darius Soonawala,Simone A. Joosten,Corine Prins,Sandra M. Arend,Peter Fibiger Bang,Pernille N. Tingskov,Karen Lingnau,Jan Nouta,Søren T. Hoff,Ida Rosenkrands,Ingrid Kromann,Tom H. M. Ottenhoff,T. Mark Doherty,Peter Andersen	104
17	Ag85B–ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers 2010 ·Vaccine ·Jaap T. van Dissel,Sandra M. Arend,Corine Prins,Peter Fibiger Bang,Pernille N. Tingskov,Karen Lingnau,Jan Nouta,Michèl R. Klein,Ida Rosenkrands,Tom H. M. Ottenhoff,Ingrid Kromann,T. Mark Doherty,Peter Andersen	166
18	First in humans: A new molecularly defined vaccine shows excellent safety and strong induction of long-livedMycobacterium tuberculosis-specific Th1-cell like responses 2010 ·Human Vaccines ·Tom H. M. Ottenhoff,T. Mark Doherty,Jaap T. van Dissel,Peter Fibiger Bang,Karen Lingnau,Ingrid Kromann,Peter Andersen	52
19	Transient Facial Nerve Paralysis (Bell's Palsy) following Intranasal Delivery of a Genetically Detoxified Mutant of Escherichia coli Heat Labile Toxin 2009 ·PLoS ONE ·D. J. Lewis,Zhiming Huo,Susan W. Barnett,Ingrid Kromann,Rafaela Giemza,Eva Galiza,(unknown),Birgit Thierry-Carstensen,Peter Andersen,Deborah L. Novicki,Giuseppe Del Giudice,Rino Rappuoli	237
20	Non-clinical efficacy and safety of HyVac4:IC31 vaccine administered in a BCG prime–boost regimen 2009 ·Vaccine ·Yasir A. W. Skeiky,Jes Dietrich,Todd Lasco,Katherine E. Stagliano,Veerabadran Dheenadhayalan,Margaret Ann Goetz,(unknown),Randall J. Basaraba,Peter Fibiger Bang,Ingrid Kromann,(unknown),Jerald Sadoff,Peter Andersen	54

About Ingrid Kromann

Ingrid Kromann is a scholar working on Infectious Diseases, Virology and Immunology, having authored 23 papers that have together received 1.4k indexed citations. Recurring topics across this work include Tuberculosis Research and Epidemiology (12 papers), vaccines and immunoinformatics approaches (10 papers) and Immunodeficiency and Autoimmune Disorders (7 papers). The work is most often cited by research in Infectious Diseases (759 citations), Immunology (828 citations) and Microbiology (170 citations). Ingrid Kromann has collaborated with scholars based in Denmark, Netherlands and United States. Frequent co-authors include Peter Andersen, Peter Fibiger Bang, Tom H. M. Ottenhoff, Jaap T. van Dissel, Birgit Thierry-Carstensen, Søren T. Hoff, Corine Prins, Lars Vibe Andreasen, Karen Lingnau and Morten Rühwald. Their work appears in journals such as The Journal of Immunology, PLoS ONE and American Journal of Respiratory and Critical Care Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact